

UNCLASSIFIED

AD NUMBER
ADB266026
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Jul 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012
AUTHORITY
USANRNC ltr, 26 Aug 2002

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-98-1-8035

TITLE: Potential Role of a Novel Nuclear Matrix Protein (nmt55)
as a Tumor Marker in Human Breast Cancer Invasion and
Metastases

PRINCIPAL INVESTIGATOR: Matthew Pavao, M.A.
Dr. Traish

CONTRACTING ORGANIZATION: Boston University School of Medicine
Boston, Massachusetts 02118-2394

REPORT DATE: July 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, Jul 00). Other requests
for this document shall be referred to U.S. Army Medical Research
and Materiel Command, 504 Scott Street, Fort Detrick, Maryland
21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20010509 085

—

Organization: Boston University School of Medicine

1

09/24/07

1000 2000 3000 4000 5000 6000 7000 8000 9000 10000 11000 12000 13000 14000 15000 16000 17000 18000 19000 20000 21000 22000 23000 24000 25000 26000 27000 28000 29000 30000 31000 32000 33000 34000 35000 36000 37000 38000 39000 40000 41000 42000 43000 44000 45000 46000 47000 48000 49000 50000 51000 52000 53000 54000 55000 56000 57000 58000 59000 60000 61000 62000 63000 64000 65000 66000 67000 68000 69000 70000 71000 72000 73000 74000 75000 76000 77000 78000 79000 80000 81000 82000 83000 84000 85000 86000 87000 88000 89000 90000 91000 92000 93000 94000 95000 96000 97000 98000 99000 100000

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 2000	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jul 99 - 30 Jun 00)		
4. TITLE AND SUBTITLE Potential Role of a Novel Nuclear Matrix Protein (nmt55) as a Tumor Marker in Human Breast Cancer Invasion and Metastases		5. FUNDING NUMBERS DAMD17-98-1-8035		
6. AUTHOR(S) Matthew Pavao, M.A. Dr. Traish				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Boston University School of Medicine Boston, Massachusetts 02118-2394 E-MAIL: mpavao@bu.edu		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, Jul 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) The goal of this proposal is to test the hypothesis that loss of expression of a novel protein contributes to tumor growth, invasion and metastases, and its expression suppresses these biological events. We have identified, isolated and partially characterized a 55 kDa nuclear matrix protein from human breast tumor cells (hence forth referred to as nmt55). This novel protein is expressed in some estrogen receptor positive (ER+) tumors but was completely absent in ER- tumors. Loss of expression of this novel protein correlated strongly with tumor size ($p < 0.03$) and loss of ER and PR ($p < 0.001$). As the tumor size increased, the expression of nmt55 was not detected at the protein level. Because increased tumor size is associated with metastases, we postulate that loss of nmt55 expression is associated with molecular and cellular changes linked to cellular differentiation leading to loss of ER expression, and development of hormone-independent tumor growth, invasion and metastases. We have cloned the cDNA for nmt55 and generated site-directed polyclonal antibodies. We are currently investigating the function of nmt55 using biochemical and molecular biology approaches. The information derived from these studies will help determine the potential role of this novel nuclear matrix protein (nmt55) as a marker of tumor progression and metastases. These studies may provide critical information needed for early detection of potentially metastatic tumors, and improve diagnosis, prognosis and in developing strategies for therapeutic management and care of breast cancer patients.				
14. SUBJECT TERMS Breast Cancer nmt55 Protein, Spicing Factor, Tumor Growth, Prognostic Marker			15. NUMBER OF PAGES 12	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Matthew Paras 7-20-00
PI - Signature Date

TABLE OF CONTENTS

	<u>Page</u>
Front Cover	
Standard Form 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body of Work / Results	6-8
References	9-10
Appendix	11

Biochemical and Molecular Characterization of a Novel Nuclear Matrix Protein in Human Breast Cancer: Relationship to Tumor Hormonal Status

Introduction:

The development of breast cancer is thought to be a multi-stage process (1). The progression of this disease is associated with cellular and molecular changes. Thus, initiation and progression may be related to loss of chromosomal material and ultimately specific gene function(s). Some of these cellular and molecular changes may be accompanied with tumor cell acquisition of metastatic potential. There is an urgent need for identification of node-negative patients whose tumors have metastatic potential. Several tumor markers have been used in assessing tumor changes linked to poor prognosis. These include loss of estrogen receptor (ER) and progesterone receptor (PR) expression (2), high blood vessel count (angiogenesis) (3), amplification of *erbB2/HER2/neu* gene (4) and decreased activity of *nm23* gene (5). None of these markers alone, however, predict with complete reliability which node-negative patients will likely relapse. We have found that primary human breast tumors express a 55 kDa nuclear protein, which is absent in estrogen receptor negative (ER-) tumors (6). This observation suggested that this protein may be related to tumor hormonal status and may represent a useful tumor marker. We have carried out preliminary studies to characterize this nuclear protein (referred to as *nmt55*) from human breast tumors and the MCF-7 cell line, using site-directed monoclonal antibodies and polyclonal antibodies. In this research, we have undertaken biochemical and molecular biology approaches to investigate the function(s) of this protein and its potential role in regulation of human breast cancer cell growth.

Results:**A. Detection of nmt55 Variants in Human Breast Tumors Using Western Blot and Immunohistochemical Analyses.**

To further our investigation of nmt55 using molecular and biochemical approaches, our laboratory generated two epitope specific anti-peptide polyclonal antibodies (pAbs) to different domains of nmt55 to investigate the role of these domains in nmt55 function. One polyclonal antibody (pAb), termed NMT4, was raised against a unique peptide in the amino terminus of nmt55 and the second pAb, NMT5, was raised against a unique peptide in the mid-region of the protein. These antibodies, along with the monoclonal antibody (mAb) NMT1 (raised against the far carboxyl terminus of nmt55), were then used to screen various human breast tumors using Western blot or immunohistochemical Analyses.

When a series of tumors were screened via Western blot, the pAbs (NMT4 and NMT5) confirmed the original data observed with mAb NMT1 (6) indicating that ER- tumors displayed decreased nmt55 protein expression as compared to ER+ tumors. Interestingly, a subset of ER+ tumors expressed nmt55 protein that was not detected by pAb NMT4 but was detected by NMT5 and NMT1 antibodies using Western blot analyses.

To determine if this observation was the result of molecular changes within the tumor that altered nmt55 protein or rather an artifact of experimental preparation of breast tissue, we used the same set of antibodies to screen paraffin embedded human breast tumors by immunohistochemistry. As was observed with Western blot analysis, a subset of tumors analyzed by immunohistochemistry expressed nmt55 protein which was detectable only with pAb NMT5 and not with pAb NMT4. Since immunohistochemistry is a powerful tool used to investigate many proteins involved in breast cancer progression and is representative of the *in vivo* tumor environment, we suggest that nmt55 is indeed expressed as a variant, with alterations in its amino terminal domain, in a subset of human breast tumors. This alteration in the amino terminus of nmt55 may have deleterious effects with respect to nmt55 function and thus may play a role in breast cancer progression.

B. Intermolecular Association of nmt55 with the Polypyrimidine Tract Associated Splicing Factor (PSF).

The predicted nmt55 amino acid sequence suggested that nmt55 contains a bipartite RNA binding domain and posses strong homology to RNA binding proteins (6-9). This indicated that nmt55 may interact with other potential RNA binding proteins and may be involved in RNA processing. Data reported in year 1 of our study indicated that nmt55 could bind RNA via solubility experiments and that nmt55 interacted with a 100 kDa protein using immunoprecipitation experiments. Using specific antibodies we determined that this 100 kDa protein represented the well characterized polypyrimidine tract binding protein associated splicing factor (PSF) (7). These observations indicate that nmt55 may play an important role in the regulation of RNA processing and cellular function.

Since evidence suggested that nmt55 is also expressed in a variant form, we wanted to investigate the domain specific interaction of nmt55 with PSF. To implement in this study, we generated three GST-nmt55 fusion protein constructs. The first construct (GST-FL) encompassed the full-length nmt55 protein (residues 1-471) fused with GST protein, the second construct (GST-NT) fused the amino terminal portion of nmt55 protein (residues 1-227) with

GST protein and the final construct (GST-CT) fused the carboxyl terminal portion of nmt55 protein (residues 227-471) with GST protein. These constructs along with GST protein alone were incubated with MCF-7 cell nuclear extracts and subjected to GST pull-down assays and Western blot analysis. Using a specific PSF mAb, we showed that PSF interacts with both the amino terminus and carboxyl terminus of nmt55.

To determine if the nmt55/PSF interaction was specific for these two proteins alone, indicating multiple protein interactions, or rather that these proteins exist in a complex with other, as yet unidentified, proteins, we incubated our GST-nmt55 constructs with purified PSF protein and observed similar results. These results did not eliminate the possibility that nmt55 and PSF are part of a multi-protein complex but suggested that, regardless of other associated proteins, nmt55 and PSF have multiple molecular contacts. Thus, disruption of these contacts or alteration in domains responsible for these interactions may result in the loss of specific protein function.

C. Association of nmt55 with Several Essential pre-mRNA Splicing Factors.

The splicing and/or alternative splicing of pre-mRNAs is a critical regulatory step and, as a result, high efficiency of this step is essential in mammalian biology (11,12). It has been reported that as many as fifty different proteins may play critical roles in the splicing of pre-mRNAs (13). Since PSF has been characterized as an essential splicing factor (7) through binding to the polypyrimidine tract in pre-mRNAs, we investigated proteins that interact with the other essential pre-mRNA domains (the 5' splice site, branch A point and 3' splice site) for their ability to associate with nmt55. Reports indicate that several factors have been characterized and their functions partially elucidated (14). The SR (serine and argine rich) family of proteins has been shown to have a critical role in pre-mRNA splicing (15, 16). These proteins are involved in several RNA binding interactions involving all three critical pre-mRNA domains (17). Inhibition of these proteins has been shown to prevent *in vitro* pre-mRNA splicing (14-17). U1A 70K protein has been shown to interact with the U1snRNP and aid in its association with the 5' splice site on the pre-mRNA (18). U2AF⁶⁵ and U2AF³⁵ proteins are critical for the recruitment of the U2 snRNP to the branch A site and 3' splice site on the pre-mRNA, respectively (19, 20).

We investigated the ability of nmt55 to interact with members of the SR, U1 and U2 family using a mAb (16H3) raised against a series of serine and argine residues (21). Utilizing immunoprecipitation and Western blot analyses with mAb 16H3, we demonstrated that nmt55 interacts with a series of proteins in a large multi-protein complex. Several members of the SR family interact with nmt55 including SRp75, SRp55, SRp40 and SRp35. nmt55 also associates with U1 70K, U2AF⁶⁵, U2AF³⁵ and Topoisomerase I. Topoisomerase I has been shown to phosphorylate members of the SR protein family and may be important for RNA processing (22). The association of nmt55 with several well characterized and essential splicing factors strongly suggests a functional role for nmt55 in pre-mRNA splicing.

Summary and significance of the studies

In previous studies, we have demonstrated that nmt55 interacts with the RNA processing protein PSF and interacts with RNA, *in situ*. We have also shown that nmt55 protein expression is decreased in ER- human breast tumors. As a result of these observations, we developed specific antibodies to various domains of nmt55 and investigated the role of these domains in human breast tumors. We have identified nmt55 variants with alterations in their amino terminus in a subset of ER+ human breast tumors using Western blot and immunohistochemical analyses.

We have generated several GST-nmt55 fusion proteins to investigate the specific nmt55 domains responsible for PSF protein binding. We determined that nmt55 has multiple molecular contacts in its amino and carboxyl terminal domains with PSF protein. Along with PSF, we have elucidated the association of nmt55 with several essential splicing factors (U1 70K, U2AF⁶⁵, U2AF³⁵, SRp75, SRp55, SRp40, SRp35 and Topoisomerase I). These observations suggest that nmt55 may play an important role in RNA metabolism and/or processing.

The association of nmt55 expression with tumor hormonal status (ER and PR) in human breast tumors and its putative function as an RNA binding splicing suggests a key role in cellular growth and function. The data obtained suggests that nmt55 binds to RNA and many RNA splicing proteins and may have an important role in regulation of RNA metabolism. This may be critical in tumor cell growth and tumor progression.

Bibliography

1. Wright K. Breast cancer: two steps closer to understanding. *Science* 250: 1659, 1990.
2. McGuire WL. Hormone Receptors: Their role in predicting prognosis and responses to endocrine therapy. *Semin. Oncol.* 5: 428-433, 1978.
3. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniowska K. and Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. *Lancet.* 340: 1120-1124, 1992.
4. Santes K and Salmon D. Radiolabeled antibody targeting of the HER2/neu oncoprotein. *Cancer Res.* 52: 1916-1920, 1992.
5. Barnes R, Masood S, Barker E, Rosengard AM, Coggin DL, Crowell T, King CR, Porter-Jordan K, Wargotz ES and Liotta LA. Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. *American Journal of Pathology.* 139: 245-250, 1991.
6. Traish AM, Huang YH, Pavao M, Pronovost M, Ashba J, McNany D. and Moreland RB. Loss of expression of a 55 kDa nuclear protein (nmt55) in estrogen receptor-negative human breast cancer. *Diagn Mol Pathol.* 6(4): 209-221, 1997.
7. Patton JG, Porro EB, Galceran J, Tempst P. and Nadal-Ginard B. Cloning and characterization of PSF, a novel pre-mRNA splicing factor. *Genes and Development.* 7: 393-406, 1993.
8. Dong B, Horowitz DS, Kobayashi R. and Krainer AR. Purification and cDNA cloning of HeLa cell p54^{nrb}, a nuclear protein with two RNA recognition motifs and extensive homology to human splicing factor PSF and *Drosophila* NONA/BJ6. *Nucleic Acids Research.* 21(17): 4085-4092, 1993.
9. Yang YS, Hanke JH, Carayannopoulos L, Craft CM, Capra JD. and Tucker PW. NonO, a Non-POU-Domain-Containing, Octamer-Binding Protein, Is the Mammalian Homolog of *Drosophila* nonA^{diss}. *Molecular and Cellular Biology.* 13(9): 5593-5603, 1993.
10. Basu A, Dong B, Krainer AR and Howe CC. The Intracisternal A-Particle Proximal Enhancer-Binding Protein Activates Transcription and Is Identical to the RNA and DNA Binding Protein p54^{nrb}/NonO. *Molecular and Cellular Biology.* 17(2): 677-686, 1997.
11. Sharp PA. On the Origin of RNA Splicing and Introns. *Cell.* 42(2): 397-400, 1985.
12. Sharp PA. Spit Genes and RNA Splicing. *Cell* 77(6): 805-15, 1994.
13. Gozani O, Patton JG and Reed R. A novel set of spliceosome-associated proteins and the essential splicing factor PSF bind stably to pre-mRNA prior to catalytic step II of the splicing reaction. *EMBO J.* 13(14): 3356-67, 1994.
14. Reed R. Mechanisms of fidelity in pre-mRNA splicing. *Curr Opin Cell Biol.* 12(3): 340-5, 2000.
15. Zahler AM, Lane WS, Stolk JA, and Roth MB. SR proteins: a conserved family of pre-mRNA splicing factors. *Genes Dev.* 6(5): 837-47, 1992.
16. Zahler AM, Neugebauer KM, Lane WS and Roth MB. Distinct functions of SR proteins in alternative pre-mRNA splicing. *Science.* 260(5105): 219-22, 1993.
17. Tacke R and Manley JL. Determinants of SR protein specificity. *Curr Opin Cell Biol.* 11(3): 358-62, 1999.
18. Query CC, Bentley RC and Keene JD. A common RNA recognition motif identified within a defined U1 RNA binding domain of the 70K U1 snRNP protein. *Cell* 57(1): 89-101, 1989.
19. Zamore PD, Patton JG and Greent MR. Cloning and domain structure of the mammalian splicing factor U2AF. *Nature.* 355(6361): 609-14, 1992.
20. Zuo P and Maniatis T. The splicing factor U2AF35 mediates critical protein-protein interactions in constitutive and enhancer-dependent splicing. *Genes Dev.* 10(11): 1356-68, 1996.

21. Neugebauer KM, Stolk JA, and Roth MB. A conserved epitope on a subset of SR proteins defines a larger family of Pre-mRNA splicing factors. *J Cell Biol.* 129(4): 899-908, 1995.
22. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunel C and Tazi J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. *Nature.* 381(6577): 80-2, 1996.

Appendix

Key Research Accomplishments

- We have detected nmt55 protein variants in a subset of human breast tumors. These nmt55 protein variants have alterations in their amino terminal region as determined by Western blot and immunohistochemical analyses using an epitope specific anti-peptide polyclonal antibody raised against the amino terminus of nmt55.
- We have determined the nmt55 domains responsible for protein interaction with the Polypyrimidine Tract Binding Protein Associated Splicing Factor (PSF). It was determined using GST-nmt55 fusion proteins and GST Pull Down Assays that nmt55 has multiple molecular contacts with PSF.
- We have identified a series of essential splicing factors (PSF, U1 70K, U2AF65, U2AF35, SRp75, SRp55, SRp40, SRp35 and Topoisomerase I) that associate with nmt55 in a multi-protein complex in human breast tumors and cell lines. These associations were determined by co-immunoprecipitation experiments coupled with Western blot analysis utilizing specific monoclonal and polyclonal antibodies.

Reportable Outcomes

Published Abstracts:

Pavao M, Moreland RB and Traish AM. "Potential Role of a Novel Nuclear Protein (nmt55) in Human Breast Cancer." Abstract, The FASEB Journal, 2000.

Poster Presentations:

Pavao M, Moreland RB and Traish AM. "Characterization of a Novel Nuclear Protein (nmt55) in Human Breast Cancer." Era of Hope: Department of Defense Breast Cancer Research Program. June 2000 (Atlanta, GA).

Pavao M, Moreland RB and Traish AM. "Potential Role of a Novel Nuclear Protein (nmt55) in Human Breast Cancer." American Society for Biochemistry and Molecular Biology. June 2000 (Boston, MA).

Pavao M, Moreland RB and Traish AM. "Identification and Characterization of a Novel Nuclear Protein (nmt55) in Human Breast Cancer." Henry I Russek Student Achievement Day. May 2000 (Boston, MA).

Pavao M, Moreland RB and Traish AM. "Characterization of nmt55 as a Potential Tumor Marker in Human Breast Cancer." Graduate Student Science Research Day. April 2000 (Boston, MA).

Pavao M, Moreland RB and Traish AM. "Potential Role of nmt55, a Novel Nuclear Protein, as a Tumor Marker in Human Breast Cancer Progression and Metastasis." Gordon Research Conference on Hormonal Carcinogenesis August 1999 (Tilton, NH)



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

26 Aug 02

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB274369
ADB256383
ADB264003
ADB274462
ADB266221
ADB274470
ADB266221
ADB274464
ADB259044
ADB258808
ADB266026
ADB274658
ADB258831
ADB266077
ADB274348
ADB274273
ADB258193
ADB274516
ADB259018
ADB231912
ADB244626
ADB256677
ADB229447
ADB240218
ADB258619
ADB259398
ADB275140
ADB240473
ADB254579
ADB277040
ADB249647
ADB275184
ADB259035
ADB244774
ADB258195
ADB244675
ADB257208
ADB267108
ADB244889
ADB257384
ADB270660
ADB274493
ADB261527
ADB274286
ADB274269
ADB274592
ADB274604

ADB274596
ADB258952
ADB265976
ADB274350
ADB274346
ADB257408
ADB274474
ADB260285
ADB274568
ADB266076
ADB274441
ADB253499
ADB274406
ADB262090
ADB261103
ADB274372